Skip to main content
  • Sign in
  • Help
BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA
Join BOPA
BOPA Join BOPA
  • Why join BOPA
  • Pricing
  • Education
    • BOPA Introduction to Cancer Course 2025
    • Courses and eLearning
    • SACT Verification Hub (Passport)
    • Resource Library
    • Cancer Hub
    • Education & Training Standards
    • Let’s Talk About SACT – a BOPA Podcast
  • About BOPA
    • About BOPA
    • Welcome to BOPA
    • Executive Committee
    • Subcommittees & working groups
    • Affiliated Groups
    • Specialist Advisory Groups
    • International Groups
    • BOPA Fellows
    • Corporate Membership
    • BOPA membership FAQs
  • Conference
    • Latest Conference 2025
    • Abstract Submission Opens 31st March
    • Past Symposiums / Conferences
  • News & Events
    • News
    • Events calendar
    • Submit event
  • Menu iconLCC
    • LCC
    • Cancer Hub
  • Join BOPA

Home » Adverse event

Adverse event

BOPA encourages its members to share helpful documents that can benefit other members.  BOPA respects the intellectual property of original authors and requires anyone who uses other members’ work to include an acknowledgment of, or reference to, the source in their version.

DISCLAIMER:
BOPA is not the author or owner of some of the documents published on our website.  BOPA as a professional interest group will share documents via its website that are of interest to BOPA members, but has no responsibility for use of the documents and for any recommendations within the documents so members must use these at their discretion. BOPA cannot accept responsibility for any errors or omissions or for any consequences from application of information in the documents attached and make no warranty, expressed or implicit with respect to the contents of this webpage. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site or document(s) downloaded from it.

Posters and abstracts on the BOPA website remain the property of the authors and anyone wishing to reference or share this work must contact the authors directly. Abstracts subsequently published in JOPP follow copyright rules from JOPP.

Last reviewed: 27/04/20 by Idalia Dávila-González

Hypersensitivity reactions to chemotherapy drugs in a public hospital Mexican

View resources
Last reviewed: 12/10/20 by Pinkie Chambers

How and where do patients present with immunotherapy adverse events?

Abstracts

View resources
Last reviewed: 18/12/19 by UK Chemotherapy Board

UKCB Medication-related osteonecrosis of the jaw (MRONJ) guidance_Dec 2019

View resources
Last reviewed: 10/07/19 by Anna Tipping

Pilot Audit for National Chemotherapy Delays

Abstracts

View resources
Last reviewed: 17/03/21 by Nicola Stoner

The Administration of Immunooncology Agents in UK Clinical Practice

Abstracts

View resources
Last reviewed: 10/07/19 by Darren Walsh

Audit of Oral Anticancer Medication Prescribing in University Hospital Waterford

Abstracts

View resources
Last reviewed: 10/07/19 by Kate Wood

Proposal for the reduction in observation time post administration of subcutaneous Herceptin

Abstracts

View resources
Last reviewed: 10/07/19 by Natalie Ford

Observational Study of Skin Toxicity with Afatinib

Abstracts

View resources
Last reviewed: 10/07/19 by Hector Mateo-Carrasco

Incidence of neutropenia in breast cancer patients receiving fixed-dose GCSF: are we underdosing patients with higher body weights?

Abstracts

View resources
Last reviewed: 10/07/19 by Nisha Shaunak

Service impact assessment of new immunotherapy agents at Guy’s and St Thomas’ Foundation Trust (GSTFT)

Abstracts

View resources
Last reviewed: 10/07/19 by I. Elkonaissi

A review of the advice provided to patients who wish to self-medicate with complementary supplements during cancer treatment, by the Medicines Information (MI) department at The Royal Marsden NHS Foundation Trust (RMH)

Abstracts

View resources
Last reviewed: 10/07/19 by Nick Duncan

An audit of Aprepitant for the prevention of nausea and vomiting after chemotherapy

Abstracts

View resources

Filter for resources

  • Types

  • Tags

  • Reset

1 2 Next
BOPA logo
  • Why join BOPA
  • Pricing/Join
  • Conference 2024
  • Education
  • About
  • News & Events
  • Help
  • Go to LinkedIn
  • Go to Twitter
  • Go to Facebook
  • Go to Instagram
  • Go to Bluesky

© Copyright 2025 British Oncology Pharmacy Association.
Registered Charity No. 1065026

  • Privacy Policy
  • T&Cs Website
  • T&Cs Membership
  • Cookies
  • Contact
Designed and developed by Rouge
Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site. By continuing to browse the site, you are agreeing to our use of cookies.